Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

Seagen

Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in combination with Merck's (MRK) Keytruda.

Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump

GlaxoSmithKline

Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. GSK's revenue was $9.12 billion in the second quarter of 2023, up 8.1% year-over-year, beating analysts' estimates by $0.38 billion. Meanwhile, Merck's revenue continued to grow quarter over quarter and reached approximately $15.04 billion for the three months ended June 30, 2023.

Merck Vs. GSK: The Game-Changer Race In Pharma Excellence

Merck's crown jewel still sparkles, and that should continue for several years. The drugmaker is on the verge of earning approval for another blockbuster medicine.

3 Reasons to Buy Merck Stock

Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals in a disappointing outcome, but said they would continue to push ahead with their research.

Merck and Eisai say two lung-cancer trials failed to meet their main goals

Merck said on Friday its cancer immunotherapy Keytruda in combination with partner Eisai's drug failed to meet main goals in a late-stage study evaluating it as a treatment for patients with a type of lung cancer.

Drugmaker Merck says Keytruda combination fails in lung cancer trial

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic NSCLC.

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS & PFS in Certain Patients With Previously Untreated la/m UC.

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Keytruda is proving effective in treating more and more types of cancer, and its long-term growth potential is massive in my view. I believe Keytruda is set to generate $31 billion revenue by the end of 2025. Januvia/Janumet's fall should not be that sharp while Gardasil/Gardasil-9 is likely to continue to do well.

Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

Merck & Co., Inc.'s payout ratios suggest that the market-beating dividend is well-covered. The company's stacked portfolio of therapies and candidates should lead to solid growth moving forward. My inputs into the discounted cash flows model show shares of Merck to be trading at a modest discount to fair value.

Merck: A Blue-Chip Dividend Stock Worth Buying

The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.

FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma

AbbVie

Amgen

CRISPR Therapeutics

Johnson & Johnson

Eli Lilly

Molina Healthcare

Novo Nordisk

Pfizer

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Flee to Healthcare Stocks if Recession Rears its Head?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Priority Review to Merck's Application for KEYTRUDA + Concurrent Chemoradiotherapy for Newly Diagnosed Locally Advanced Cervical Cancer.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck's strong performance in the past two years, driven by Keytruda and Lagevrio, has outperformed the market by an impressive 52%. MRK's acquisition of Prometheus Biosciences signals its effort to diversify beyond Oncology and Vaccines, strategically preparing for the Keytruda patent expiration in 2028. The company is set to achieve a 5% annualized EPS growth, maintaining stable profitability, and offering a secure 2.71% dividend, with dividend annual growth of 5-6%.

Merck: Secure A Safe 8% Annualized Return For The Next Decade

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts for Priority Review Merck's Supplemental New Drug Application for WELIREG® in Certain Previously Treated Patients With Advanced RCC.

FDA Accepts for Priority Review Merck's Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in the EU.

Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for NSCLC at High Risk of Recurrence Following Resection and Chemotherapy.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Merck & Co., Inc. (NYSE:MRK ) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 2:15 PM ET Company Participants Dean Li - President Caroline Litchfield - Chief Executive Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Hi, everybody. Thanks for joining us this afternoon.

Merck & Co., Inc. (MRK) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Pulmonary Arterial Hypertension (PAH).

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.

Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe

Gilead Sciences

abrdn Healthcare Investors 

iShares Nasdaq Biotechnology ETF

Illumina

IQVIA Hlds

Direxion Daily S&P Biotech Bull 3X Shares

Lonza Group AG

Navistar

Omega Healthcare Investors

Royalty Pharma

abrdn World Healthcare Fund 

Wuxi Biologics Cayman Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Investors can consider diversified biotech indexes or healthcare-focused ETFs for exposure to the biopharma sector.

Biopharma Bounce-Back: From Policy Pains To Profitable Plains

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

Rollins

Schwab US Dividend Equity ETF

Snap-on

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 0.57% in August, outperforming the S&P 500 by 1.02%. Year-to-date, the portfolio is up 14.07%. Since inception, the portfolio is generating 3.95% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Closing In On A Historic First Year

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Expands Merck's ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older.

European Commission Expands Merck's ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

News for Merck Stock (MRK)